Pricing Log in Create free account

IRulya Therapeutics Inc. (IRLA) vs Metagenomi Therapeutics, Inc. (MGX)

IRulya Therapeutics Inc. and Metagenomi Therapeutics, Inc. are both Biotechnology companies. IRulya Therapeutics Inc. and Metagenomi Therapeutics, Inc. are of similar size ($29.8M and $27.6M). IRulya Therapeutics Inc. has the higher net margin (0.00% vs −689.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, IRulya Therapeutics Inc. leads on 7 and Metagenomi Therapeutics, Inc. on 4.

Valuation

Metric IRLA MGX Biotechnology median
P/E n/m n/m 10.60
P/S n/m 1.94 9.40
P/B n/m 0.23 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.66 0.66
EV/Sales n/m (4.72) 9.02
Earnings yield (463.25%) (355.71%) (32.88%)
Free cash flow yield (25.09%) (325.47%) (23.13%)

Profitability

Metric IRLA MGX Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (741.58%) 0.00%
Net margin 0.00% (689.20%) 0.00%
Free cash flow margin 0.00% (632.67%) 0.00%
Return on equity 784.09% (60.61%) (51.96%)
Return on assets (76.68%) (41.91%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IRLA MGX Biotechnology median
Revenue growth (TTM) — (59.84%) 6.76%
EPS growth (last fiscal year) (28.24%) 0.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IRLA MGX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.52 4.50 4.97
Net debt to EBITDA 0.00 1.71 1.01

Dividend

Metric IRLA MGX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IRLA MGX Biotechnology median
Market cap 29.81m 27.60m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack